G. Béra

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau et al. · The Lancet Oncology · 2020 · 124 citations

Radiation Therapy, Medicine, High-dose Cisplatin Chemoradiotherapy +9

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Yungan Tao, Xu-Shan Sun, Y. Pointreau et al. · European Journal of Cancer · 2023 · 48 citations · Full text

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Martin Boegemann, Sara Khaksar, G. Béra et al. · BMC Cancer · 2019 · 41 citations · Full text

Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients

Aurore Goineau, L. Campion, Bénédicte d’Aillières et al. · PLoS ONE · 2018 · 29 citations · Full text